In Romania, several patients suffering from obstructive hypertrophic cardiomyopathy are turning to the judiciary to obtain reimbursement for an innovative treatment from the public healthcare service. As reported by the news outlet HotNews, people affected by this pathology face the concrete risk of sudden death and severe physical limitations, but the drug is not yet included in the registries of products covered by the state.

The affair has involved citizens who had started treatment thanks to a temporary donation program, which recently ended. One patient won the dispute in the first instance, securing the supply of the medicines for six months, but the Ministry of Health and the National Health Insurance House have filed an appeal, the hearing of which is expected in December.

According to evaluations provided by cardiologist Robert Adam of the C.C. Iliescu Institute in Bucharest, there could be around five thousand patients in the country eligible for this specific therapeutic path. The autonomous purchase of the preparation entails a monthly expenditure ranging between one thousand five hundred and eight thousand lei, figures that broadly exceed the economic means of many workers affected by the disease.

The CardioGen association has promoted petitions with about two thousand four hundred signatures to ask the authorities for public coverage of the costs. Patient representatives emphasize that guaranteeing access to the drug allows people to continue working, reducing sick leave and emergency hospital admissions.